Streetbeat News

Price Targets

HLT

In the last 3 months, 7 analysts have provided 12-month price targets for Hilton Worldwide Holdings (NYSE:HLT), with an average price target of $156.71. The ratings include 3 somewhat bullish and 4 indifferent ratings.

Portfolio Pulse from Benzinga Insights

June 27, 2023 | 3:00 pm

PANW

Palo Alto Networks' stock is trading higher after Morgan Stanley maintained an Overweight rating and raised its price target from $255 to $302.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 2:19 pm

ACET

Guggenheim analyst Michael Schmidt downgraded Adicet Bio (NASDAQ:ACET) from Buy to Neutral and announced a $20 price target.

Portfolio Pulse from richadhand@benzinga.com

June 27, 2023 | 2:19 pm

CARA

Jefferies analyst Dennis Ding reiterated a Buy rating on Cara Therapeutics (NASDAQ:CARA) and maintained an $18 price target.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2023 | 1:50 pm

ARHS

Craig-Hallum analyst Jeremy Hamblin initiates coverage on Arhaus (NASDAQ:ARHS) with a Buy rating and announces a price target of $15.

Portfolio Pulse from richadhand@benzinga.com

June 27, 2023 | 1:46 pm

ALKT

Lake Street analyst Jacob Stephan initiates coverage on Alkami Technology (NASDAQ:ALKT) with a Buy rating and announces a price target of $21.

Portfolio Pulse from richadhand@benzinga.com

June 27, 2023 | 1:45 pm

AVTA

Barrington Research analyst Alexander Paris reiterated an Outperform rating on Avantax (NASDAQ:AVTA) and maintained a $32.5 price target.

Portfolio Pulse from richadhand@benzinga.com

June 27, 2023 | 1:40 pm

META

Citigroup analyst Ronald Josey maintains a Buy rating on Meta Platforms (NASDAQ:META) and raises the price target from $315 to $360.

Portfolio Pulse from richadhand@benzinga.com

June 27, 2023 | 1:39 pm

VKTX

Truist Securities analyst Joon Lee has reiterated a Buy rating on Viking Therapeutics (NASDAQ:VKTX) and maintained a $32 price target.

Portfolio Pulse from richadhand@benzinga.com

June 27, 2023 | 1:35 pm

VRNA

Truist Securities analyst Joon Lee has reiterated a Buy rating on Verona Pharma (NASDAQ:VRNA) and maintained a $32 price target.

Portfolio Pulse from richadhand@benzinga.com

June 27, 2023 | 1:34 pm